Highline Capital Management

Highline Capital Management, L.P., is a New York City-based investment firm that focuses on mid and large capitalization U.S. equities long and short. Since its establishment in 1995, Highline has performed fundamental research to create portfolios with attractive risk/return profiles. Highline prides itself on producing a successful risk-adjusted track record relative to comparative U.S. equity market indices. Historically, Highline Capital Management has invested in late-stage biotechnology, healthcare, and life sciences companies, focusing on North America and Europe, with a presence in Philadelphia, Ann Arbor, and Munich. The firm's latest investment was in Network Bio in February 2025. Network Bio offers biomedical data for AI-enabled precision medicine.